Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2305–2328 of 85,906 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 1 Clear all

Conditions: Parkinson's Disease
Interventions: tDCS; Device
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Hypoparathyroidism
Interventions: PTH1-84 in parent study; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 85 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Colorectal Cancer
Interventions: FOLFIRI regimen, fluorouracil, irinotecan hydrochloride, leucovorin calcium, semaxanib; Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Sepsis, Respiratory Failure, Agitation
Interventions: Propofol, Dexmedetomidine, Fentanyl; Drug
Lead sponsor: Texas Tech University Health Sciences Center; Other
Eligibility: 18 Years to 89 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Advanced Hepatocellular Carcinoma, Cirrhosis, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
Interventions: Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Multigated Acquisition Scan, Zanzalintinib; Procedure · Drug
Lead sponsor: Devalingam Mahalingam; Other
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Vinorelbine, Docetaxel, Gemcitabine, Carboplatin; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: COPD
Interventions: Transcutaneous Electrical Muscle Stimulation (TCEMS), Sham TCEMS; Procedure · Other
Lead sponsor: Yale University; Other
Eligibility: Up to 75 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Tobacco Use
Interventions: CSD170202AA, CSD170202AB; Other
Lead sponsor: RAI Services Company; Industry
Eligibility: 21 Years and older
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Stockbridge, Georgia

Conditions: Clostridium Infections, Diarrhea
Interventions: PAR-101/OPT-80, Vancomycin; Drug
Lead sponsor: Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 16 Years and older
Enrollment: 535 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 53
States / cities: Gadsden, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 50 more

Conditions: a Diagnosis of MGUS or SMM by IMWG Criteria
Interventions: Not listed
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Problem of Aging
Interventions: injectable poly-L-lactic acid; Drug
Lead sponsor: Williams Center Plastic Surgery Specialists; Other
Eligibility: 40 Years to 60 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Latham, New York

Conditions: Tobacco Use Disorders
Interventions: Varenicline, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 16 Years to 19 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Neurofibromatosis 1 (NF1), Neurofibromatosis Type I
Interventions: GentleMax Pro (with skin cooling), GentleMax Pro (without skin cooling); Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Acute Lymphoblastic Leukemia, B-cell Non Hodgkin Lymphoma, Pre B-Cell Acute Lymphoblastic Leukaemia
Interventions: Blinatumomab 9ug, Blinatumomab 28 ug, Blinatumomab, Dexamethasone; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Grade II Glioma, Grade III Glioma, Grade IV Glioma, Astrocytoma, Oligodendroglioma of Brain, Anaplastic Astrocytoma of Brain, Anaplastic Oligodendroglioma, Glioblastoma
Interventions: Microdevice; Combination Product
Lead sponsor: Oliver Jonas; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Preterm Prelabor Rupture of Membranes, PPROM
Interventions: Azithromycin (Azithro), Standard Azithromycin Dosing; Drug
Lead sponsor: Alexa Henderson; Other
Eligibility: Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: COPD, Chronic Bronchitis
Interventions: Losartan 50 mg, Losartan 100 mg; Drug
Lead sponsor: University of Miami; Other
Eligibility: 35 Years to 75 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Suicidal Thoughts and Behaviors, Social Isolation
Interventions: Qnnections, Enhanced Usual Care; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: San Diego, California

Conditions: Overactive Bladder With Urge Urinary Incontinence
Interventions: URO-902, Placebo; Drug
Lead sponsor: Urovant Sciences GmbH; Industry
Eligibility: 40 Years to 79 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 20
States / cities: Mobile, Alabama • Tucson, Arizona • Laguna Hills, California + 17 more

Conditions: Healthy
Interventions: [13C]Pantoprazole; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 49 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Schizophrenia
Interventions: d-cycloserine; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Oropharynx Cancer
Interventions: Carboplatin, Radiation Therapy, Paclitaxel; Drug · Radiation
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 2
States / cities: Ann Arbor, Michigan

Conditions: Stage IV Adrenocortical Carcinoma
Interventions: Antineoplaston therapy (Atengenal + Astugenal); Drug
Lead sponsor: Burzynski Research Institute; Other
Eligibility: 6 Months to 99 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Weight Loss
Interventions: Standard Behavioral Weight Loss Intervention (SBWL), Campaign Intervention (CI); Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 55 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Search by objective public record fields.

Open Label Treatment With tDCS for Parkinson's and Related Disorders for Improvement of Speech, Gait and Mood

ADD-ON Study to Existing Hypoparathyroidism Studies

Combination Chemotherapy With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer

Study of Sedative Medications in Patients With Severe Infection and Respiratory Failure

Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer

The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer

Rehabilitation of Patients With COPD Using Electrical Muscle Stimulation

CSD170202: A Study to Evaluate the Exposure to Tobacco Constituents From Two Moist Snuff Products

PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)

Study Of Circulating Multiple Myeloma Cells As A Biomarker of MGUS And SMM

Volume Restoration of the Aging Midface With Sculptra Aesthetic

Varenicline on Reward Responses and Cognition in Adolescent Smokers

Assessing the Efficacy of Repeat, Monthly Treatments of Alexandrite Laser for NF1-associated Cutaneous Neurofibromas (cNFs)

A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance

Implantable Microdevice In Primary Brain Tumors

Extended Azithromycin Treatment in Prelabor Rupture of Membranes

Effect of Losartan on Airway Mucociliary Dysfunction in Patients With COPD and Chronic Bronchitis

Qnnections: Refinement and Pilot Trial of a Suicide Prevention Intervention to Increase Social Connection

URO-902 in Female Subjects With Overactive Bladder and Urge Urinary Incontinence

Rapid Screening Phenotype Test To Evaluate CYP 2C19 Enzyme Activity Using Stable Isotope [13C]Pantoprazole

Effects of Weekly Dosing of D-cycloserine on Cognitive Function in Individuals With Schizophrenia

Individualized Adaptive De-escalated Radiotherapy for HPV-related Oropharynx Cancer

Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer

Feasibility of a Campaign Intervention Compared to a Standard Behavioral Weight Loss Intervention in Overweight and Obese Adults